Oligonucleotide solid nucleolipid nanoparticles against antibiotic resistance of ESBL-producing bacteria

Phuoc Vinh Nguyen (1) , Clémentine Aubry (1) , Narimane Boudaoud (1) , Alexandra Gaubert (1) , Marie-Hélène Langlois (1) , Mathieu Marchivie (2) , Karen Gaudin (1) , Corinne Arpin (3) , Philippe Barthélémy (1) , Tina Kauss (1)

1 ARNA - Acides Nucléiques : Régulations Naturelle et Artificielle
2 ICMCB - Institut de Chimie de la Matière Condensée de Bordeaux
3 MFP - Microbiologie Fondamentale et Pathogénicité

Antibiotic resistance has become a major issue in the global healthcare system, notably in the case of Gram-negative bacteria. Recent advances in technology with oligonucleotides have an enormous potential for tackling this problem, providing their efficient intrabacterial delivery. The current work aimed to apply this strategy by using a novel nanoformulation consisting of DOTAU, a nucleolipid carrier, in an attempt to simultaneously deliver antibiotic and anti-resistance oligonucleotides. Ceftriaxone, a third-generation cephalosporin, was formulated with DOTAU to form an ion pair, and was then nanoprecipitated. The obtained solid nanocapsules were characterized using FT-IR, XRD, HPLC, TEM and DLS techniques and further functionalized by the anti-resistance ONα sequence. To obtain an optimal anti-resistance activity and encapsulation yield, both the formulation protocol and the concentration of ONα were optimized. As a result, monodispersed negatively charged nanoparticles of CFX–DOTAU-ONα with a molar ratio of 10:24:1 were obtained. The minimum inhibitory concentration of these nanoparticles on the resistant Escherichia coli strain was significantly reduced (by 75%) in comparison with that of non-vectorized ONα. All aforementioned results reveal that our nanoformulation can be considered as an efficient and relevant strategy for oligonucleotide intrabacterial delivery in the fight against antibiotic resistance

Mots clés: oligonucleotides; antibiotic resistance; solid nanoparticles; nanocapsules; ESBL-producing E. coli; nucleolipid; nucleic acids; CTX-M15 ß-lactamase

Domaines: Pharmacie galénique; Maladies infectieuses; Bactériologie

Phuoc Vinh Nguyen, Clémentine Aubry, Narimane Boudaoud, Alexandra Gaubert, Marie-Hélène Langlois, et al.. Oligonucleotide solid nucleolipid nanoparticles against antibiotic resistance of ESBL-producing bacteria. Pharmaceutics, 2022, 14 (2), pp.299. ⟨10.3390/pharmaceutics14020299⟩. ⟨hal-03603893⟩